NCT00163059View on ClinicalTrials.gov

The Antidepressant Effects Of The NMDA Antagonist, CP-101,606, In Patients With MDD

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 31, 2004

Study Completion Date

December 31, 2005

Conditions
Depressive Disorder, Major
Interventions
DRUG

NMDA Antagonist, CP-101,606 (traxoprodil)

Trial Locations (1)

67214-2878

Pfizer Investigational Site, Wichita

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY